Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Trelegy Ellipta and Lung Function Improvement
Help improve lung function for COPD patients with a once-daily single-inhaler Triple Therapy 2,7
Breathing Better: How single-inhaler Triple Therapy could help your patients with COPD from today
Over 50% of patients treated with COPD maintenance therapies, including ICS/LABA, continue to suffer from breathlessness4
TRELEGY Ellipta provides statistically superior lung function improvement vs.budesonide/formoterol2
TRELEGY Ellipta provides statistically superior lung function improvement vs.a LAMA/LABA (UMEC/VI)3
Statistically superior improvement in lung function vs. budesonide/formoterol2
Adapted from Lipson et al. 20172
Data from the FULFIL study comparing TRELEGY Ellipta OD to BUD/FOR.2 Co-primary endpoints of change from baseline in trough FEV1 and SGRQ score at Week 24 were both met. Further information on the FULFIL study lower down this page
*MCID: Minimal Clinically Important Difference. Patients with COPD have been shown to perceive an improvement of ≥100 mL in trough FEV1 as beneficial5
Statistically superior improvement in lung function vs. a LAMA/LABA (UMEC/VI)3,6
Adapted from Lipson et al. 20183,6
Data from the IMPACT Trial comparing TRELEGY Ellipta OD to an ICS/LABA (FF/VI) and a LAMA/LABA (UMEC/VI).3,6 Primary endpoints of annual rate of on-treatment moderate/severe exacerbations for TRELEGY Ellipta vs. both comparators were met. Change from baseline in trough FEV1 at Week 52 was a secondary endpoint
Key trial design
-
FULFIL study design²
FULFIL was a Phase III, randomised, double-blind, double-dummy, parallel-group, multicentre, 24-week study designed to assess the efficacy and safety of the single-inhaler triple therapy TRELEGY Ellipta OD (FF/UMEC/VI) vs. budesonide/formoterol with an extension to 52 weeks in a subset of patients.2
Co-primary endpoints:
- Change from baseline in trough FEV1 and SGRQ score at Week 24
Secondary endpoints include:
- Annual rate of moderate/severe COPD exacerbations
- Change from baseline CAT score
Key inclusion criteria:
- Patients with COPD with a FEV1 <50% and a CAT score ≥10, or
- Patients with a FEV1 ≥50% to <80% and a CAT score ≥10, and either ≥2 moderate exacerbations in the past year or ≥1 severe exacerbation in the past year*
- Aged ≥40 years
Key exclusion criteria:
- Current diagnosis of asthma causing patient symptoms
- Unresolved pneumonia or severe COPD exacerbation
*A moderate exacerbation was defined as having worsening symptoms of COPD that required treatment with oral/ systemic corticosteroids and/or antibiotics. A severe exacerbation was defined as worsening symptoms of COPD that required treatment with inpatient hospitalisation
-
IMPACT trial design³
IMPACT is the first trial to assess, over 52 weeks, the efficacy and safety of the single-inhaler triple therapy TRELEGY Ellipta (FF/UMEC/VI) vs. an ICS/LABA (FF/VI) and vs. a LAMA/LABA (UMEC/VI), in symptomatic patients on COPD maintenance treatments who had experienced at least one exacerbation in the last 12 months.3
Primary endpoints:
- Annual rate of on-treatment moderate/severe exacerbations* for TRELEGY Ellipta vs. both comparators
Secondary endpoints include:
- Lung function: change from baseline in trough FEV1 at Week 52
- Health-related quality of life: change from baseline in SGRQ score at Week 52
Other endpoints include:
- On-treatment all-cause mortality
Key inclusion criteria:
- Patients aged 40 years or older with COPD and a CAT score ≥10 with:
- FEV1 <50% predicted and ≥1 moderate/severe exacerbation in the previous year, or
- FEV1 ≥50% to <80% predicted and ≥2 moderate exacerbations or ≥1 severe exacerbation in the previous year
- FEV1 <50% predicted and ≥1 moderate/severe exacerbation in the previous year, or
- Patients were required to be receiving daily maintenance therapy for COPD for at least 3 months prior to screening
Key exclusion criteria:
- Current diagnosis of asthma or other respiratory disorders
- Unresolved pneumonia or COPD exacerbation, or respiratory tract infection ≤14 days or 7 days, respectively
- Oral/systemic corticosteroid use ≤30 days prior to screening
*A moderate exacerbation was defined as an exacerbation leading to treatment with antibiotics or systemic glucocorticoids. A severe exacerbation was one resulting in hospitalisation or death
Get started with Trelegy Ellipta
Footnotes
BD, twice daily; BUD, budesonide; CAT, COPD assessment test; CI, confidence interval; FEV1, forced expiratory volume in one second; FF, fluticasone furoate; FOR, formoterol; ICS, inhaled corticosteroid; LABA, long-acting ß2-agonist; LAMA, long-acting muscarinic antagonist; LS, least squares; OD, once daily; MCID, minimal clinically important difference; SGRQ, St George’s Respiratory Questionnaire; UMEC, umeclidinium; VI, vilanterol
TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA¹
References
- TRELEGY Ellipta SmPC, 2022. Available at https://www.medicines.ie. Accessed October 2022.
- Lipson DA et al. Am J Crit Care Med 2017; 196:438–446.
- Lipson DA et al. N Engl J Med 2018; 378:1671–1680.
- Rebordosa C et al. Pharmacoepidemiol Drug Saf 2019; 28:126–133, including supplementary material.
- Jones PW et al. Am J Respir Crit Care Med 2014; 189:250–255.
- GSK, Data on File. RF/TLY/0067/18. IMPACT Study: trough FEV1 data over 52 weeks.
- Tabberer M et al. Adv Ther 2018; 35:56–71.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Trelegy is a registered trademark of the GlaxoSmithKline group of companies.
TRELEGY Ellipta was developed in collaboration with
Last Updated: October 2022 PM-IE-FVU-WCNT-220014
